Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice

Neuropharmacology

Volumn 86, Issue , 2014, Pages 192-202

  Patil, Sachin P ^a   Jain, Pankaj D ^a   Sancheti, Jayant S ^a   Ghumatkar, Priya J ^a   Tambe, Rufi ^a   Sathaye, Sadhana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Apigenin; Luteolin; Neuroprotective; Neurotrophic; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APIGENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LUTEOLIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; NEUROPROTECTIVE AGENT; CATALASE; GLUTATHIONE; PROBENECID; SUPEROXIDE DISMUTASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; LOCOMOTION; MALE; MICROGLIA; MOUSE; MPTP-INDUCED PARKINSONISM; MUSCLE CONTRACTION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SUBSTANTIA NIGRA PARS COMPACTA; AMINO ACID BRAIN LEVEL; ANTIOXIDANT ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; OPEN FIELD TEST; PARKINSON DISEASE; PARKINSONISM; ROTAROD TEST;

ANIMALS; APIGENIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; LUTEOLIN; MALE; MICE; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARS COMPACTA; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 84907311915     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.07.012     Document Type: Article

References (54)

1. H. Aebi Catalase H.U. Bergmeyer, Methods of Enzymatic Analysis vol. 2 1974 Academic Press, Inc. New York 673 684
2. K.S. Bhullar, and H.P.V. Rupasinghe Polyphenols: multipotent therapeutic agents in neurodegenerative diseases Oxid. Med. Cell. Longev. 2013 1 18
3. D.K. Binder, and H.E. Scharfman Brain-derived neurotrophic factor Growth Factors 22 2004 123 131 (Pubitemid 39377904)
4. A.R. Carta, E. Carboni, and S. Spiga The MPTP/Probenecid model of progressive Parkinson's disease Methods Mol. Biol. 964 2013 295 308
5. R.J. Carter, A.J. Morton, and S.B. Dunnett Motor coordination and balance in rodents Curr. Protoc. Neurosci. 2001 1 14 8.12
6. H. Chen, Z. Jin, X. Wang, X. Xu, L. Deng, and J. Zhao Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation 448 2008 175 179
7. H. Cui, Y. Kong, and H. Zhang Oxidative stress, mitochondrial dysfunction, and aging J. Signal Transduct. 2012 1 13
8. K.P. Datla, M. Christidou, W.W. Widmer, H.K. Rooprai, and D.T. Dexter Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease Neuroreport 12 2001 3871 3875 (Pubitemid 33105188)
9. S.C. Daubner, T. Le, and S. Wang Tyrosine hydroxylase and regulation of dopamine synthesis Arch. Biochem. Biophys. 508 2011 1 12
10. T. Fukuda, J. Takahashi, and J. Tanaka Tyrosine Hydroxylase- immunoreactive neurons are decreased in number in the cerebral cortex of Parkinson's disease Neuropathology 19 1999 10 13 (Pubitemid 29101433)
11. M. Funakoshi-Tago, K. Nakamura, K. Tago, T. Mashino, and T. Kasahara Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin Int. Immunopharmacol. 11 2011 1150 1159
12. G.J. Gage, D.R. Kipke, and W. Shain Whole animal perfusion fixation for rodents J. Vis. Exp. 65 2012 1 9
13. A.J. Gearing, P. Beckett, M. Christodoulou, M. Churchill, J. Clements, A.H. Davidson, A.H. Drummond, W.A. Galloway, R. Gilbert, and J.L. Gordon et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases Lett. Nat. 370 1994 555 557 (Pubitemid 24264920)
14. T.D. Gould, D.T. Dao, and C.E. Kovacsics The open field test Neuromethods 42 2009 1 20
15. B. Halliwell, and S. Chirico Lipid peroxidation: its mechanism, measurement, and significance Am. J. Clin. Nutr. 57 1993 15S 25S
16. A. Hartmann Postmortem studies in Parkinson's disease Dialogues Clin. Neurosci. 6 2004 281 293 (Pubitemid 39362560)
17. S. Hunot, N. Dugas, B. Faucheux, A. Hartmann, M. Tardieu, D. Patrice, Y. Agid, B. Dugas, and E.C. Hirsch FcqRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells J. Neurosci. 19 1999 3440 3447 (Pubitemid 29203124)
18. V. Jackson-Lewis, and S. Przedborski Protocol for the MPTP mouse model of Parkinson's disease Nat. Protoc. 2 2007 141 151 (Pubitemid 47044700)
19. J. Jankovic Parkinson's disease: clinical features and diagnosis J. Neurol. Neurosurg. Psychiatry 79 2008 368 376 (Pubitemid 351441488)
20. P. Jenner, and C.W. Olanow Oxidative stress and the pathogenesis of Parkinson's disease Neurology 47 1996 161 170
21. P. Johannsen, G. Velander, J. Mai, E.B. Thorling, and E. Dupont Glutathione peroxidase in early and advanced Parkinson's disease J. Neurol. Neurosurg. Psychiatry 54 1991 679 682
22. X. Li Improved pyrogallol autoxidation method: a reliable and cheap superoxide-scavenging assay suitable for all antioxidants J. Agric. Food Chem. 60 2012 6418 6424
23. J.H. Lim, K.M. Kim, S.W. Kim, O. Hwang, and H.J. Choi Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage Pharmacol. Res. 57 2008 325 331
24. C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability Am. J. Clin. Nutr. 79 2004 727 747 (Pubitemid 41103873)
25. N.J. Maragakis, and J.D. Rothstein Mechanisms of Disease: astrocytes in neurodegenerative Disease Nat. Clin. Practice:Neurol. 2 2006 679 689 (Pubitemid 44782682)
26. S. Matsuda, M. Umeda, H. Uchida, H. Kato, and T. Araki Alterations of oxidative stress markers and apoptosis markers in the striatum after transient focal cerebral ischemia in rats J. Neural Transm. 116 2009 395 404
27. W.G. Meissner, M. Frasier, T. Gasser, C.G. Goetz, A. Lozano, and P. Piccini Priorities in Parkinson's disease research Nat. Rev. Drug. Discov. 10 2011 377 393
28. H. Mochizuki Adult neurogenesis in Parkinson's disease Neurogenesis Adult Brain II 2011 23 36
29. P. Mohapel, H. Frielingsdorf, J. Häggblad, O. Zachrisson, and P. Brundin Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions Neuroscience 132 2005 767 776
30. M.C. Morale, P.A. Serra, F. L'episcopo, C. Tirolo, S. Caniglia, N. Testa, F. Gennuso, and G. Giaquinta et al. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration Neuroscience 138 2006 869 878
31. D. Muralikrishnan, and K.P. Mohanakumar Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice FASEB 12 1998 905 912 (Pubitemid 28294680)
32. A. Nandi, and I.B. Chatterjee Assay of superoxide dismutase activity in animal tissues J. Biosci. 13 1988 305 315
33. H. Ohkawa, O. Nobuko, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358 (Pubitemid 9194347)
34. C. Perier, and M. Vila Mitochondrial biology and Parkinson's disease Cold Spring Harb. Perspect. Med. 4 2012 1 19
35. S. Przedborski, and M. Vila MPTP: a review of its mechanisms of neurotoxicity Clin. Neurosci. Res. 1 2001 407 418 (Pubitemid 33665559)
36. C.A. Reilly, and S.D. Aust Measurement of lipid peroxidation Curr. Protoc. 1999 1 13 2.4
37. K. Rezai-Zadeh, J. Ehrhart, Y. Bai, P.R. Sanberg, P. Bickford, J. Tan, and R.D. Shytle Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression J. Neuroinflam. 5 2008 1 10
38. M. Sakuma, N. Hayakawa, H. Kato, and T. Araki Time dependent changes of striatal interneurons after focal cerebral ischemia J. Neural Transm. 115 2008 413 422
39. J.B. Salgueiro, P. Ardenghi, M. Dias, M.B. Ferreira, I. Izquierdo, and J.H. Medina Anxiolytic natural and synthetic flavonoids ligands of the central benzodiazepine receptor have no effect on memory tasks in rats Pharmacol. Biochem. Behav. 58 1997 887 891 (Pubitemid 28108193)
40. J. Sedlak, and R.H. Lindsay Estimation of total and non-protein sulfydral groups in tissues with Ellman's reagent Anal. Biochem. 95 1968 351 358
41. J.A. Serra, R.O. Dominguez, E.S. de Lustig, E.M. Guareschi, A.L. Famulari, E.L. Bartolome, and E.R. Marschoff Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients J. Neural Transm. 108 2001 1135 1148 (Pubitemid 33022763)
42. Y.H. Siddique, F. Naz, S. Jyoti, and M. Afzal Protective effect of apigenin in transgenic Drosophila Melanogaster model of Parkinson's disease Pharmacologyonline 3 2011 790 795
43. A.K. Sinha Calorimetric assay of catalase Anal. Biochem. 47 1972 389 394
44. I.K. Smith, T.L. Vierheller, and C.A. Thorne Assay of glutathione reductase in crude tissue homogenates using 5,5'-dithiobis(2-nitrobenzoic acid) Anal. Biochem. 175 1988 408 413
45. P. Taupin Apigenin and related compounds stimulate adult neurogenesis Expert Opin. Ther. Patents 19 2009 523 527
46. J.M. Taylor, B.S. Main, and P.J. Crack Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease Neurochem. Int. 62 2013 803 819
47. D. Tweedie, K. Sambamurti, and N.H. Greig TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets Curr. Alzheimer Res. 4 2007 378 385 (Pubitemid 47421968)
48. H. Viola, C. Wasowski, M. Levi de Stein, C. Wolfman, R. Silveira, F. Dajas, J.H. Medina, and A.C. Paladini Apigenin, a component of Matricaria recutitaflowers, is a central benzodiazepine receptors-ligand with anxiolytic effects Planta Med. 61 1995 213 216
49. A.M. Weissmiller, and C. Wu Current advances in using neurotrophic factors to treat neurodegenerative disorders Transl. Neurodegener. 1 2012 1 9
50. C.J. Weydert, and J.J. Cullen Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue Nat. Protoc. 5 2009 51 66
51. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 2007 963 976 (Pubitemid 46628616)
52. K.A. Youdim, M.S. Dobbie, G. Kuhnle, A.R. Proteggente, N.J. Abbott, and C. Rice-Evans Interaction between flavonoids and the blood-brain barrier: in vitro studies J. Neurochem. 85 2003 180 192 (Pubitemid 36389708)
53. K.A. Youdim, M.Z. Qaiser, D.J. Begley, C.A. Rice-Evans, and N.J. Abbott Flavonoid permeability across an in situ model of the blood-brain barrier Free Radic. Biol. Med. 36 2004 592 604 (Pubitemid 38230176)
54. J. Zhang, G. Perry, M.A. Smith, D. Robertson, S.J. Olson, D.G. Graham, and T.J. Montine Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons Am. J. Pathol. 154 1999 1423 1429 (Pubitemid 29226437)